BR112016029129A2 - compostos ppar para serem utilizados no tratamento de doenças fibróticas. - Google Patents

compostos ppar para serem utilizados no tratamento de doenças fibróticas.

Info

Publication number
BR112016029129A2
BR112016029129A2 BR112016029129-8A BR112016029129A BR112016029129A2 BR 112016029129 A2 BR112016029129 A2 BR 112016029129A2 BR 112016029129 A BR112016029129 A BR 112016029129A BR 112016029129 A2 BR112016029129 A2 BR 112016029129A2
Authority
BR
Brazil
Prior art keywords
treatment
fibrotic disorders
ppar compounds
ppar
compounds
Prior art date
Application number
BR112016029129-8A
Other languages
English (en)
Inventor
Konstantinova Irena
Luccarini Jean-Michel
Louis JUNIEN Jean-
Broqua Pierre
Original Assignee
Inventiva
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inventiva filed Critical Inventiva
Publication of BR112016029129A2 publication Critical patent/BR112016029129A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

a invenção se refere ao uso de um agonista pan-ppar, ou de uma composição farmacêutica contendo o referido agonista, para o tratamento de uma condição fibrótica.
BR112016029129-8A 2014-06-13 2015-06-12 compostos ppar para serem utilizados no tratamento de doenças fibróticas. BR112016029129A2 (pt)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
EP14305897.2 2014-06-13
EP14305896 2014-06-13
EP14305897 2014-06-13
EP14305895 2014-06-13
EP14305894 2014-06-13
EP14305895.6 2014-06-13
EP14305896.4 2014-06-13
EP14305894.9 2014-06-13
EP14307187.6 2014-12-24
EP14307187 2014-12-24
PCT/EP2015/063196 WO2015189401A1 (en) 2014-06-13 2015-06-12 Ppar compounds for use in the treatment of fibrotic diseases.

Publications (1)

Publication Number Publication Date
BR112016029129A2 true BR112016029129A2 (pt) 2018-01-30

Family

ID=53373480

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016029129-8A BR112016029129A2 (pt) 2014-06-13 2015-06-12 compostos ppar para serem utilizados no tratamento de doenças fibróticas.

Country Status (24)

Country Link
US (2) US10052311B2 (pt)
EP (1) EP3154543B1 (pt)
JP (1) JP6557684B2 (pt)
KR (1) KR102347721B1 (pt)
CN (1) CN106573058B (pt)
AU (1) AU2015273454B2 (pt)
BR (1) BR112016029129A2 (pt)
CA (1) CA2951337C (pt)
CY (1) CY1122264T1 (pt)
DK (1) DK3154543T3 (pt)
EA (1) EA036342B1 (pt)
ES (1) ES2755183T3 (pt)
HR (1) HRP20191941T1 (pt)
HU (1) HUE046293T2 (pt)
IL (1) IL249458B (pt)
MX (1) MX2016016534A (pt)
PL (1) PL3154543T3 (pt)
PT (1) PT3154543T (pt)
RS (1) RS59426B1 (pt)
SI (1) SI3154543T1 (pt)
TN (1) TN2016000535A1 (pt)
UA (1) UA120851C2 (pt)
WO (1) WO2015189401A1 (pt)
ZA (1) ZA201608281B (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210267983A1 (en) * 2018-07-13 2021-09-02 Kinarus Ag Combinations of ppar agonists and p38 kinase inhibitors for preventing or treating fibrotic diseases
FR3084254B1 (fr) 2018-07-27 2020-10-23 Inventiva Derives deuteres du lanifibranor
CN110934866B (zh) * 2018-09-25 2023-12-01 深圳微芯生物科技股份有限公司 西格列羧及其相关化合物的应用
US11504380B2 (en) 2019-11-08 2022-11-22 Inventiva Method of treatment of cirrhosis
WO2021161218A1 (en) * 2020-02-11 2021-08-19 Inorbit Therapeutics Ab Sulfinic acid and sulfonic acid compounds for use in modulating peroxisome proliferator-activated receptors
EP4000616A1 (en) 2020-11-17 2022-05-25 Inventiva Combination therapy for the treatment of a liver disease
WO2022122014A1 (zh) 2020-12-11 2022-06-16 苏州科睿思制药有限公司 Lanifibranor的晶型及其制备方法和用途
CN114058694A (zh) * 2021-11-29 2022-02-18 上海市普陀区中心医院 Trpv1在筛选或制备预防、缓解和/或治疗肝脏疾病的药物中的应用
KR20230143965A (ko) 2022-04-06 2023-10-13 (주)샤페론 타우로데옥시콜린산 또는 이의 약학적으로 허용가능한 염을 유효성분으로 함유하는 폐섬유증 예방 또는 치료용 조성물
WO2023220332A1 (en) * 2022-05-13 2023-11-16 Children's Hospital Medical Center Methods and compositions for treatment of idiopathic pulmonary fibrosis

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004103296A2 (en) 2003-05-16 2004-12-02 Intermune, Inc. Methods of treating idiopathic pulmonary fibrosis
FR2890071B1 (fr) * 2005-08-30 2007-11-09 Fournier Sa Sa Lab Nouveaux composes de l'indole
CN101304992A (zh) * 2005-09-07 2008-11-12 普莱希科公司 用作ppar调节剂的1,3-二取代吲哚衍生物
JP5248747B2 (ja) * 2006-01-19 2013-07-31 キッセイ薬品工業株式会社 アディポネクチン受容体発現賦活薬
JP2007112720A (ja) * 2005-10-18 2007-05-10 Kissei Pharmaceut Co Ltd メタボリックシンドローム予防又は治療薬
CA2726588C (en) 2008-06-03 2019-04-16 Karl Kossen Compounds and methods for treating inflammatory and fibrotic disorders
EP2229951A1 (en) 2009-03-08 2010-09-22 Stichting Katholieke Universiteit Methods for the treatment or prevention of systemic sclerosis
CA2781451C (en) 2009-11-26 2019-04-16 Genfit Use of 1,3-diphenylprop-2-en-1-one derivatives for treating liver disorders
CN103038232B (zh) 2010-05-26 2016-01-20 阿德弗里奥药品有限责任公司 单独的和与PDE5抑制剂相组合的sGC刺激剂、sGC活化剂用于治疗系统性硬化症(SSc)的用途
WO2012159107A1 (en) 2011-05-19 2012-11-22 Rhode Island Hospital Inhibition of renal fibrosis
CN104023718B (zh) 2011-10-28 2017-04-05 鲁美纳医药公司 用于治疗高胆血症和胆汁淤积性肝病的胆汁酸再循环抑制剂
WO2013071077A1 (en) * 2011-11-09 2013-05-16 Cornell University The use of pan-ppar agonists for prevention and treatment of huntington's disease and tauopathies
WO2014013005A1 (en) 2012-07-18 2014-01-23 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preventing and treating chronic kidney disease (ckd)

Also Published As

Publication number Publication date
ES2755183T3 (es) 2020-04-21
US20180333396A1 (en) 2018-11-22
MX2016016534A (es) 2017-04-06
CA2951337A1 (en) 2015-12-17
AU2015273454B2 (en) 2019-09-05
EA201692433A1 (ru) 2017-05-31
ZA201608281B (en) 2018-05-30
IL249458B (en) 2020-08-31
HUE046293T2 (hu) 2020-02-28
HRP20191941T1 (hr) 2020-01-10
DK3154543T3 (da) 2019-12-02
CY1122264T1 (el) 2020-11-25
US20170189383A1 (en) 2017-07-06
TN2016000535A1 (en) 2018-04-04
RS59426B1 (sr) 2019-11-29
EP3154543A1 (en) 2017-04-19
PL3154543T3 (pl) 2020-02-28
JP6557684B2 (ja) 2019-08-07
SI3154543T1 (sl) 2019-12-31
CN106573058A (zh) 2017-04-19
AU2015273454A1 (en) 2017-01-05
US10383858B2 (en) 2019-08-20
CN106573058B (zh) 2020-05-05
EA036342B1 (ru) 2020-10-29
CA2951337C (en) 2022-08-23
JP2017524663A (ja) 2017-08-31
WO2015189401A1 (en) 2015-12-17
KR20170042504A (ko) 2017-04-19
PT3154543T (pt) 2019-11-04
KR102347721B1 (ko) 2022-01-05
UA120851C2 (uk) 2020-02-25
EP3154543B1 (en) 2019-08-28
IL249458A0 (en) 2017-02-28
US10052311B2 (en) 2018-08-21

Similar Documents

Publication Publication Date Title
BR112016029129A2 (pt) compostos ppar para serem utilizados no tratamento de doenças fibróticas.
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
MA41265A (fr) Compositions pour administration de médicaments iléo-jéjunal.
ZA201802451B (en) 2,4-dihydroxy-nicotinamides as apj agonists
ZA202003662B (en) Ppar agonists, compounds, pharmaceutical compositions, and methods of use thereof
EP3140291A4 (en) Tetrahydroquinoline sulfonamide and related compounds for use as agonists of rory and the treatment of disease
DK3107901T3 (da) Forbindelser til brug som gpr120 agonister
BR112017002060A2 (pt) novo uso
CL2016003074A1 (es) Compuestos derivados de 2-oxi-2-fenil-n-5-pirrolidin-3-ilamino-1,3,4-tiadiazol-2-ilacetamida, inhibidores gls1 composición farmacéutica y su uso para tratar el cáncer.
SG11201705194XA (en) Pharmaceutical composition for treating diabetes
CL2019001038A1 (es) Composición para el cuidado bucal.
FR3020758B1 (fr) Composition pour ameliorer l'hygiene buco-dentaire
CL2016002321A1 (es) Compuestos derivados del ácido 2-8-5-cloropirimidin-2-ilamino-6,7,8,9-tetrahidro-5h-pirido3,2-bindol-5-ilacético, moduladores del receptor de prostaglandina d2 composición farmacéutica y su uso para el tratamiento de enfermedadestrastornos alérgicosinmunitarios.
EA201691924A1 (ru) Фармацевтические композиции
CL2019001624A1 (es) Composición para el cuidado bucal.
CL2019000323A1 (es) Composición para el cuidado bucal.
BR112016015578A2 (pt) Inibidores de 17beta-hidroxiesteroide desidrogenases tipo 1 e tipo 2
GB2558845B (en) Petrified cellulosic materials as additives to treatment fluids
RU2014154366A (ru) Применение пробиотического штамма микроорганизма enterococcus faecium l3 для лечения нейродегенеративных заболеваний
PH12016502466A1 (en) Ppar compounds for use in the treatment of fibrotic diseases
AP2017009784A0 (en) Anthostema senegalense-based composition, for use as an anti-aids drug
BR112017004882A2 (pt) composição farmacêutica oral.
ITUB20155450A1 (it) Composizione per il trattamento delle dermatiti.
TH1501005765A (th) องค์ประกอบที่ใช้สำหรับช่องปาก
TH1501004634A (th) องค์ประกอบที่ใช้สำหรับช่องปาก

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]